Compare Merck & Co., Inc. (MRK) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nvidia Corp — how do they compare? Merck & Co., Inc. trades at $141.84 (market cap $352.29B), while Nvidia Corp trades at $234.24 (market cap $5.73T). The key difference: Nvidia Corp is far larger — about 16.3× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.38%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Nvidia Corp for 115 Days on average.
| MRK | NVDA | |
|---|---|---|
Market Cap | $352.29B | $5.73T |
Volume | 6,348,796 | 81,027,431 |
Sector | Health | Technology |
52-Week High | $156.43 | $239.27 |
52-Week Low | $82.49 | $165.17 |
Typical Hold Time | 98 Days | 115 Days |
Enterprise Value | $399.05B | $5.71T |
Dividend Yield | 2.38% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
NVIDIA (NVDA) trades at $237.36, down 0.8% on the day, amid strong fundamental performance with revenue surging to $130.5 billion in 2025 and net income reaching $72.88 billion. The stock maintains a bullish technical outlook with moving averages signaling strength, though RSI levels suggest potential overbought conditions. Recent earnings beats and a 75.95% analyst buy rating support positive sentiment, while the company's dominant position in AI chips drives continued growth expectations.
Outlook remains positive with a consensus price target of $339.17 representing significant upside potential. Key opportunities include sustained AI demand and expanding market leadership, while risks involve increased competition, peak AI spending concerns, and valuation metrics above industry averages. The stock's current valuation reflects high growth expectations that must be met to justify further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
